N/A
Completed N=146
Acceptability and Efficacy of the Zemedy App for Irritable Bowel Syndrome
Source: ClinicalTrials.gov NCT04170686 ↗Enrolled (actual)
146
Serious AEs
0.0%
Results posted
Dec 2020
Primary outcomePrimary: Irritable Bowel Syndrome Quality of Life — 34.25; 58.19 score on a scale
Summary
The purpose of this research is to assess if a new self-help app for IBS is an acceptable and effective intervention for improving the overall quality of life in patients with Irritable Bowel Syndrome.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Irritable Bowel Syndrome Quality of Life |
34.25; 58.19 | — |
| PRIMARY Gastrointestinal Symptom Rating Scale |
27.56; 38.18 | — |
| SECONDARY Visceral Sensitivity Index |
38.14; 53.57 | — |
| SECONDARY GI Cognitions Questionnaire |
22.44; 40.84 | — |
| SECONDARY Fear of Food Questionnaire |
41.22; 53.75 | — |
| SECONDARY Patient Health Questionnaire |
5.78; 10.32 | — |
| SECONDARY Depression Anxiety and Stress Scale - Depression Subscale |
7.83; 15.45 | — |
| SECONDARY Depression Anxiety and Stress Scale - Stress Subscale |
12.72; 18.82 | — |
| SECONDARY Depression Anxiety and Stress Scale - Anxiety Subscale |
8.67; 12.05 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of IBS. Own a smart phone. Speak English
Exclusion Criteria
- Under age of consent (18) Diagnosed with another GI disorder (e.g. celiac disease, inflammatory bowel disease)
Data sourced from ClinicalTrials.gov (NCT04170686). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.